论文部分内容阅读
目的探讨胃癌组织中鸟嘌呤核苷酸解离抑制因子(Rho GDI)2的表达与临床病理的关系及可能机制。方法 60例胃癌患者,取相邻的胃癌癌旁组织为对照组。检测两组Rho GDI2的表达,并对Rho GDI2的表达与胃癌临床病理进行统计学分析。结果胃癌组织中Rho GDI2的表达水平明显高于癌旁组织(P<0.05);胃癌组织中Rho GDI2表达的阳性率(76.67%)显著高于癌旁组织(45.00%)(χ2=2.491 8,P=0.012 7);胃癌组织中Rho GDI2的表达与病理分期、分化程度、淋巴结转移、肿瘤大小有显著相关性(P<0.05);胃癌组织中Rho GDI2及MMP2表达水平明显高于癌旁组织(P<0.01);罗格列酮作用后胃癌组织中Rho GDI2 mRNA、MMP2 mRNA的表达水平明显低于作用前(P<0.01);罗格列酮作用前和作用后胃癌组织中Rho GDI2与MMP2的表达之间呈正相关(rs=0.595,P=0.000;rs=0.612,P=0.000)。结果 Rho GDI2在胃癌中呈高表达;胃癌中Rho GDI2的表达参与了胃癌的发病、转移和进展;罗格列酮可以抑制Rho GDI2的表达;Rho GDI2可能通过调控MMP2的表达参与胃癌的发病、转移及进展。
Objective To investigate the relationship between the expression of guanosine nucleotide dissociation inhibitor (Rho GDI) 2 and clinicopathological features in gastric cancer and its possible mechanism. Methods 60 cases of gastric cancer patients, adjacent gastric cancer adjacent tissues as the control group. The expression of Rho GDI2 in both groups was detected, and the expression of Rho GDI2 and clinicopathological features of gastric cancer were statistically analyzed. Results The positive expression rate of Rho GDI2 in gastric cancer was significantly higher than that in paracancer tissues (76.67% vs 45.00%, χ2 = 2.491 8, P <0.05) P = 0.012 7). The expression of Rho GDI2 in gastric cancer tissues was significantly correlated with the pathological stage, differentiation degree, lymph node metastasis and tumor size (P <0.05). The expression of Rho GDI2 and MMP2 in gastric cancer tissues was significantly higher than that in paracancerous tissues (P <0.01). The expressions of Rho GDI2 mRNA and MMP2 mRNA in gastric cancer tissues after rosiglitazone treatment were significantly lower than those before the treatment (P <0.01). The expressions of Rho GDI2 and MMP2 expression was positively correlated (rs = 0.595, P = 0.000; rs = 0.612, P = 0.000). Results Rho GDI2 was highly expressed in gastric cancer. The expression of Rho GDI2 in gastric cancer was involved in the pathogenesis, metastasis and progression of gastric cancer. Rosiglitazone could inhibit the expression of Rho GDI2. Rho GDI2 may be involved in the pathogenesis of gastric cancer by regulating the expression of MMP2, Transfer and progress.